---
tags:
  - clinical
aliases:
  - Obesity
  - guidance on obesity management
  - Weight loss
---
See [[lipids]] & [[diabetes treatment]]


semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Mounjaro), orlistat (Alli, Xenical), and phentermine-topiramate (Qsymia).

# Centrally acting

# Peripherally acting
### Orlistat
The patient should be reviewed three months after commencing orlistat, and it is generally only continued if the weight loss is 5% of total weight or more. The new guidelines make an exception in type 2 diabetes, where a lower target could be discussed with the patient. 